潤邁德-B(02297.HK)完成配售2.34億股 淨籌約3747萬港元
格隆匯6月20日丨潤邁德-B(02297.HK)宣佈,認購協議所載的所有先決條件已獲達成,並已於2025年6月20日完成。
合共233,559,800股股份(佔(i)公司於公告日期之現有已發行股本約20.00%;及(ii)公司經配發及發行認購股份擴大後的已發行股本約16.67%)已按認購價每股股份0.163港元成功發行予認購人。
緊隨認購事項完成後,認購人將根據聯交所證券上市規則第14A章被視爲公司的主要股東及關連人士。
公司自認購事項收取所得款項淨額總額約3747萬港元,並擬按先前公告「認購事項之理由及所得款項用途」一節所披露方式動用所得款項淨額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.